Tactile Systems Technology (NASDAQ:TCMD) Shares Gap Down on Analyst Downgrade

Key Points

• BTIG Research lowered its price target for Tactile Systems Technology from $35 to $31, prompting the stock to gap down, but it maintained a Buy rating. Analysts overall rate TCMD “Moderate Buy,” with an average target price of $36.80.
• Tactile Medical reported third-quarter adjusted EPS of $0.31, beating the $0.28 consensus estimate, while revenue of $91.86 million was roughly in line with expectations. Its core lymphedema product revenue grew 13% year over year to $81.8 million.
• Growth was offset by weakness in the AffloVest business, inventory challenges and higher operating expenses. The company reaffirmed fiscal 2026 revenue guidance of $360 million to $366 million, while institutional investors own 83.43% of the stock.

Shares of Tactile Systems Technology, Inc. (NASDAQ:TCMD - Get Free Report) gapped down before the market opened on Tuesday after BTIG Research lowered their price target on the stock from $35.00 to $31.00. The stock had previously closed at $22.87, but opened at $21.54. BTIG Research currently has a buy rating on the stock. Tactile Systems Technology shares last traded at $23.7580, with a volume of 54,576 shares trading hands.

TCMD has been the subject of a number of other reports. Weiss Ratings upgraded shares of Tactile Systems Technology from a "hold (c)" rating to a "hold (c+)" rating in a report on Tuesday, October 13th. Wall Street Zen upgraded shares of Tactile Systems Technology from a "buy" rating to a "strong-buy" rating in a report on Saturday. Four investment analysts have rated the stock with a Buy rating and two have assigned a Hold rating to the company's stock. According to data from MarketBeat.com, Tactile Systems Technology has an average rating of "Moderate Buy" and an average target price of $36.80.

Insider Transactions at Tactile Systems Technology

In other Tactile Systems Technology news, CEO Sheri Dodd sold 10,978 shares of Tactile Systems Technology stock in a transaction on Monday, August 10th. The shares were sold at an average price of $29.44, for a total value of $323,192.32. Following the transaction, the chief executive officer directly owned 232,907 shares of the company's stock, valued at approximately $6,856,782.08. The trade was a 4.50% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Corporate insiders own 2.10% of the company's stock.

Trending Headlines about Tactile Systems Technology

Here are the key news stories impacting Tactile Systems Technology this week:

• Positive Sentiment: Third-quarter adjusted earnings were $0.31 per share, above the $0.28 consensus estimate. Revenue was $91.86 million, essentially in line with the $91.99 million estimate. Tactile Systems Technology quarterly earnings report
• Positive Sentiment: The core lymphedema business continued to expand, with product revenue rising 13% year over year to $81.8 million. Management also said technology improvements cut medical-record review times by roughly 50%, potentially supporting operating efficiency over time. Tactile Systems long-term investor takeaways
• Positive Sentiment: BTIG Research maintained a Buy rating and continues to see substantial upside, although it lowered its price target from $35 to $31. Wall Street Zen also upgraded its rating on TCMD. BTIG Research rating
• Neutral Sentiment: Tactile Medical reaffirmed fiscal 2026 revenue guidance of $360 million to $366 million, a range that broadly brackets the $362.5 million analyst consensus. This suggests expectations remain intact but does not represent a clear forecast upgrade.
• Negative Sentiment: The smaller AffloVest airway-clearance business continued to contract, while inventory challenges deepened. Higher sales and administrative expenses also pushed operating income below the prior-year level, and quarterly EPS declined from $0.36 a year earlier. Tactile Medical earnings analysis
• Negative Sentiment: The reduction in BTIG’s target price signals more cautious near-term expectations despite the continued Buy rating. Investors may therefore focus on whether lymphedema growth can offset AffloVest weakness and spending pressure.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently added to or reduced their stakes in TCMD. BlackRock Inc. purchased a new stake in Tactile Systems Technology in the second quarter valued at about $56,733,000. First Light Asset Management LLC purchased a new stake in shares of Tactile Systems Technology during the second quarter worth about $13,775,000. Renaissance Technologies LLC increased its holdings in shares of Tactile Systems Technology by 32.3% during the first quarter. Renaissance Technologies LLC now owns 510,897 shares of the company's stock valued at $13,350,000 after acquiring an additional 124,597 shares in the last quarter. Jupiter Topco LLC acquired a new position in shares of Tactile Systems Technology during the second quarter valued at about $11,831,000. Finally, Punch & Associates Investment Management Inc. acquired a new position in shares of Tactile Systems Technology during the second quarter valued at about $9,381,000. 83.43% of the stock is currently owned by hedge funds and other institutional investors.

Tactile Systems Technology Trading Up 4.2%

The stock has a market capitalization of $539.52 million, a PE ratio of 22.06 and a beta of 0.82. The company's 50-day moving average is $22.72 and its 200 day moving average is $25.91.

Tactile Systems Technology (NASDAQ:TCMD - Get Free Report) last released its earnings results on Monday, November 2nd. The company reported $0.31 earnings per share for the quarter, topping the consensus estimate of $0.28 by $0.03. The company had revenue of $91.86 million for the quarter, compared to the consensus estimate of $91.99 million. Tactile Systems Technology had a net margin of 7.10% and a return on equity of 11.49%. Sell-side analysts forecast that Tactile Systems Technology, Inc. will post 1.10 EPS for the current fiscal year.

About Tactile Systems Technology

Tactile Systems Technology, doing business as Tactile Medical, develops and provides medical devices and services for people with chronic swelling and related conditions. The company focuses primarily on lymphedema and chronic venous insufficiency, conditions that can cause persistent fluid buildup in the limbs and trunk.

Its principal products include advanced pneumatic compression devices, such as the Flexitouch Plus system for the treatment of lymphedema and the Entre Plus system for home treatment of lymphedema and chronic venous insufficiency.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.